EFFECTS OF CINOBUFACIN ON TH17, TREG CELLS, RELATED CYTOKINES AND TUMOR MARKERS IN THE PERIPHERAL BLOOD OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

Jianlun Zeng^*, Zhibing Lu, Xingzhi Huang, Ruijuan Li

Department of Oncology, Pingxiang People's Hospital, Pingxiang, PR China

Objective: To explore the effect of cinobufacin on Th17, Treg cells, related cytokines and tumor markers in the peripheral blood of patients with non-small cell lung cancer. 

Methods: The clinical records of NSCLC patients treated in our hospital from May 2017 to March 2018 were analyzed. According to the different treatment methods, patients were divided into an experimental group and a control group, with 44 cases in each group. The control group received routine chemotherapy with the NSCLC program. The experimental group was treated with cinobufacin on the basis of the control group. The adverse reactions of the two groups were observed and the auxiliary of the two groups were compared, including cell 17 (Th17 cell), regulatory T cell (Treg cell), interleukin-17 (IL-17), transforming growth factor-β (TGF-β), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron specific enolase (NSE), serum carbohydrate antigen 125 (CA125), and tumor suppressor. Furthermore, the changes of the P53 antibody and HIF-1 were observed. 

Results: Compared with the before treatment, Th17 cells in the two groups increased significantly, while Treg cells decreased significantly (P<0.01); however, compared with the control group, Th17 cells in the experimental group increased significantly and Treg cells decreased significantly (P<0.05). After treatment, compared with the control group, the level of IL-17 in the experimental group was significantly higher, and the levels of IFN-γ, TNF-α and TGF-β were significantly lower (P<0.05). After treatment, compared with the control group, CEA, CYFRA21-1, NSE and CA125 levels in the experimental group decreased significantly (P<0.05). After treatment, compared with the control group, the levels of P53 and HIF-1 α in the experimental group decreased significantly (P<0.05). However, the side effects of the experimental group were significantly less than that of the control group (P<0.05). 

Conclusion: Cinobufacin combined with chemotherapy is safe for NSCLC patients. Moreover, it can effectively reduce the side effects of chemotherapy, improve quality of life and the survival rate of NSCLC patients, as well as reduce the pain and tolerance of patients, improve immune function and the total effective rate of treatment, and play an anti-cancer role.